Previous 10 | Next 10 |
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer injections First and only treatment approved in wAMD and DME for immediate do...
2023-08-18 15:00:03 ET More on the market Jackson Hole: Fed Faces Ghosts Of 1970s As Stock Market Rollercoaster Continues Resolving An Overbought Condition For The Stock Market Dollar Bulls Still In Control Why I Stopped Buying The S&P 500 To Buy REITs Inst...
2023-08-18 14:23:01 ET More on Regeneron Pharmaceuticals Regeneron could see share price bounce with potential approvals Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefro...
CHAPLE is an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms Approval represents 10 th FDA-approved medicine invented by Regeneron With the approval of Veopoz, the pre-approval inspection issues r...
2023-08-18 13:10:25 ET AARP and Public Citizen have each filed amicus curiae briefs in a case in a Ohio federal court that is challenging the Inflation Reduction Act's plan that allows for Medicare prescription drug price negotiations. The organizations' briefs back the federal governme...
2023-08-17 12:12:00 ET Summary Bronte Capital is an Australian-licensed and USA SEC-registered Global Fund Manager and focuses on generating alpha from both its long and short portfolio in a unique, uncorrelated and sustainable manner. The Amalthea fund shed 1.35% in June whereas ...
2023-08-17 09:28:09 ET More on Regeneron Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefront Regeneron: Eylea Hype Past, But '23 H2 Will Be A Gut Check Regeneron could se...
TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for odronextamab to treat adult patients with relapsed/refractory (R/R) ...
2023-08-15 15:44:44 ET More on Regeneron Pharmaceuticals Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefront Regeneron: Eylea Hype Past, But '23 H2 Will Be A Gut Check For fu...
2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...